NHeLP Comments to the Senate Finance Committee on the High Price of Prescription

Executive Summary

NHeLP letter to the Senate Finance Committee in response to the request for public comment on policy issues including the financial impact of high prices of breakthrough drugs, data on prescription drug costs, and ensuring patient access, particularly for low income and vulnerable populations. Commments follow after an 18 month investigation into Gilead and the pricing of breakthrough treatments for hepatitis C, including Sovaldi and Harvoni.

Related Content

For almost 50 years, the National Health Law Program has fought to expand access to quality health care to low-income individuals and underserved communities. Today we are pleased to launch a newly designed website for our future work to make health care a reality for all people. Please take time to peruse our new site, and sign up for our email updates to learn about us, watch the work we do, and become engaged.

Continue to site